Using a new treatment to boost the immune response in melanoma patients before surgery
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma
This study is testing a new treatment for patients with high-risk melanoma by combining two medicines, CMP-001 and Nivolumab, to see if they can help the immune system better fight the cancer while keeping side effects low.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11053566 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat high-risk melanoma patients by combining a specific immunotherapy agent, CMP-001, with Nivolumab, an anti-PD-1 antibody. The treatment is administered intratumorally to enhance the immune system's ability to recognize and attack melanoma cells. The goal is to evaluate how effective and safe this combination therapy is in patients who have not previously received PD-1 blockade. By assessing the immune response and potential side effects, the study aims to improve outcomes for patients undergoing surgery for melanoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with high-risk, resectable stage III melanoma who have not previously been treated with PD-1 blockade.
Not a fit: Patients with melanoma that is not resectable or those who have previously received PD-1 blockade may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective pre-surgical treatments for melanoma, potentially reducing the risk of cancer recurrence.
How similar studies have performed: Previous studies have shown promising results with similar immunotherapy approaches, suggesting potential for success in this novel combination treatment.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Zarour, Hassane M — University of Pittsburgh at Pittsburgh
- Study coordinator: Zarour, Hassane M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.